Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study
Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study
L. V. Van Gaal,J. Broom,2 Authors,the Spanish Milnacipran/Imipramine Study Group
1998 · DOI: 10.1007/s002280050433
European Journal of Clinical Pharmacology · 140 Citations
TLDR
Weight-reducing efficacy of orlistat, a novel gastrointestinal lipase inhibitor, and to define the optimal dosage regimen and establish the tolerability of the drug when used for a 6-month treatment period are determined.